Begin main content

Drug Reimbursement Recommendation

Published on: August 29, 2019
Result type: News

Today, CADTH has issued final recommendations for:

Daratumumab (Darzalex) in combination with bortezomib, melphalan and prednisone for newly diagnosed multiple myeloma

Funding Request: In combination with bortezomib, melphalan and prednisone, for the treatment of patients with newly diagnosed multiple myeloma who are not suitable for autologous stem cell transplant.
Recommendation: Reimburse with clinical criteria and/or conditions
Notification to implement target date: September 16, 2019

For more information

Trifluridine and Tipiracil (Lonsurf) Resubmission for Metastatic Colorectal Cancer

Funding Request: Treatment of adult patients with mCRC who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents
Recommendation: Do not reimburse
Notification to implement target date: September 16, 2019

For more information